The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial
Open accessAbstract
BACKGROUND & AIMS: Rifaximin-α is efficacious for the prevention of recurrent hepatic encephalopathy (HE), but its mechanism of action remains unclear. We postulated that rifaximin-α reduces gut microbiota-derived endotoxemia and systemic inflammation, a known driver of HE. METHODS: In a placebo-controlled, double-blind, mechanistic study, 38 patients with cirrhosis and HE were randomised 1:1 to receive either rifaximin-α (550 mg BID) or placebo for 90 days. PRIMARY OUTCOME: 50% reduction in neutrophil oxidative burst (OB) at 30 days. SECONDARY OUTCOMES: changes in psychometric hepatic encephalopathy score (PHES) and neurocognitive functioning, shotgun metagenomic sequencing of saliva and faeces, plasma and faecal metabolic profiling, whole blood bacterial DNA quantification, neutrophil toll-like receptor (TLR)-2/4/9 expression and plasma/faecal cytokine analysis. RESULTS: Patients were well-matched: median MELD (11 rifaximin-α vs. 10 placebo). Rifaximin-α did not lead to a 50% reduction in spontaneous neutrophil OB at 30 days compared to baseline (p = 0.48). However, HE grade normalised (p = 0.014) and PHES improved (p = 0.009) after 30 days on rifaximin-α. Rifaximin-α reduced circulating neutrophil TLR-4 expression on day 30 (p = 0.021) and plasma tumour necrosis factor-α (TNF-α) (p <0.001). Rifaximin-α suppressed oralisation of the gut, reducing levels of mucin-degrading sialidase-rich species, Streptococcus spp, Veillonella atypica and parvula, Akkermansia and Hungatella. Rifaximin-α promoted a TNF-α- and interleukin-17E-enriched intestinal microenvironment, augmenting antibacterial responses to invading pathobionts and promoting gut barrier repair. Those on rifaximin-α were less likely to develop infection (odds ratio 0.21; 95% CI 0.05-0.96). CONCLUSION: Rifaximin-α led to resolution of overt and covert HE, reduced the likelihood of infection, reduced oralisation of the gut and attenuated systemic inflammation. Rifaximin-α plays a role in gut barrier repair, which could be the mechanism by which it ameliorates bacterial translocation and systemic endotoxemia in cirrhosis. CLINICAL TRIAL NUMBER: ClinicalTrials.gov NCT02019784. LAY SUMMARY: In this clinical trial, we examined the underlying mechanism of action of an antibiotic called rifaximin-α which has been shown to be an effective treatment for a complication of chronic liver disease which effects the brain (termed encephalopathy). We show that rifaximin-α suppresses gut bacteria that translocate from the mouth to the intestine and cause the intestinal wall to become leaky by breaking down the protective mucus barrier. This suppression resolves encephalopathy and reduces inflammation in the blood, preventing the development of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Alterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Self-citationThe IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
Albillos, A., Lario, M., & Álvarez-Mon, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.010 · Cited by 1,242 · cited 1×
“(5) Bacterial translocation(BT) is a significant driver of cirrhosis-associated immune dysfunction(CAID), although the mechanisms by which intestinal dysbiosis drives immune cell dysfunction remain unknown.(6,7) Furthermore, there is growing evidence supporting a pivotal role of dysregulated gut microbiota in HE, as w…”
BackgroundAltered profile of human gut microbiome is associated with cirrhosis and its complications
Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., White, M. B., Monteith, P., Noble, N. A., Unser, A. B., Daita, K., Fisher, A. R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.019 · Cited by 1,099 · cited 1×
“Gut microbiome pertubations are linked to the pathogenesis of cirrhosis and progression to advanced liver disease.(26) Over 75,000 microbial genes differ between patients with cirrhosis and healthy individuals with over 50% taxonomically assigned bacterial species of oral origin, suggesting an invasion of the distal g…”
BackgroundLinkage of gut microbiome with cognition in hepatic encephalopathy
Bajaj, J. S., Ridlon, J. M., Hylemon, P. B., Thacker, L. R., Heuman, D. M., Smith, S., Sikaroodi, M., & Gillevet, P. M. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00190.2011 · Cited by 547 · cited 2×
“(4) In cirrhosis there is an imbalance between healthy and pathogenic gut bacteria with skewed microbiota populations in favour of increased numbers of pro-inflammatory and ammoniaproducing species including Enterobacteriaceae, Firmicutes, Archaea and Prevotella.”
BackgroundDona, A. C., Jiménez, B., Schäfer, H., Humpfer, E., Spraul, M., Lewis, M. R., Pearce, J. T. M., Holmes, E., Lindon, J. C., & Nicholson, J. K. (2014) · Analytical Chemistry · doi:10.1021/ac5025039 · Cited by 540 · cited 1×
“(18) Samples were thawed and prepared for NMR using previously published protocols.(19, 20) Whole blood 16S ribosomal DNA quantification: This was undertaken by quantitative polymerase chain reaction (PCR) by Vaiomer (Labège, France).”
MethodBajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430 · cited 6×
“Rifaximin- reduces circulating endotoxin levels(4) but previous studies have fallen short of demonstrating any distinct changes in microbial abundance by 16S rRNA faecal microbiota profiling.(4,11) One study demonstrated a significant increase in potentially beneficial serum fatty acids and intermediates of carbohydr…”
BackgroundMethodInfluentialSalivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy
Bajaj, J. S., Betrapally, N. S., Hylemon, P. B., Heuman, D. M., Daita, K., White, M. B., Unser, A., Thacker, L. R., Sanyal, A. J., Kang, D. J., et al. (2015) · Hepatology · doi:10.1002/hep.27819 · Cited by 325 · cited 1×
“(27) Salivary dysbiosis is also observed in cirrhotic patients.(28) Our data confirm salivary dysbiosis with bacteria normally associated as being resident in the oral cavity translocating to the gut and associated with the”
BackgroundXu, D., Gao, J., Gillilland, M., Wu, X., Song, I., Kao, J. Y., & Owyang, C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.10.026 · Cited by 271 · cited 1×
“Previous studies have also shown rifaximin promotes the growth of beneficial strains in ulcerative colitis(35) and in a mouse model of visceral hyperalgesia, Lactobacilli grew in the ileum in response to rifaximin.(36) Rifaximin reduced adhesion, invasion and motility of E.”
Result
Cited by
Intestinal Barrier in Human Health and Disease
Di Tommaso, N., Gasbarrini, A., & Ponziani, F. R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312836 · Cited by 533
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 436
Promises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Metadata
- Authors
- Patel, V. C., Lee, S., McPhail, M. J. W., Da Silva, K., Guilly, S., Zamalloa, A., Witherden, E., Støy, S., Manakkat Vijay, G. K., Pons, N., Galleron, N., Huang, X., Gencer, S., Coen, M., Tranah, T. H., Wendon, J. A., Bruce, K. D., Le Chatelier, E., Ehrlich, S. D., Edwards, L. A., Shoaie, S., & Shawcross, D. L.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 76
- Issue
- 2
- Pages
- 332-342
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3202289966
- Cited by
- 227
- References
- 12
- FWCI
- 15.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. https://app.cochat.ai/papers/10.1016/j.jhep.2021.09.010
- The paper
- Patel, V. C., Lee, S., McPhail, M. J. W., Da Silva, K., Guilly, S., Zamalloa, A., Witherden, E., Støy, S., Manakkat Vijay, G. K., Pons, N., Galleron, N., Huang, X., Gencer, S., Coen, M., Tranah, T. H., Wendon, J. A., Bruce, K. D., Le Chatelier, E., Ehrlich, S. D., . . . Shawcross, D. L. (2022). Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.09.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.